JP2024511052A5 - - Google Patents
Info
- Publication number
- JP2024511052A5 JP2024511052A5 JP2023557358A JP2023557358A JP2024511052A5 JP 2024511052 A5 JP2024511052 A5 JP 2024511052A5 JP 2023557358 A JP2023557358 A JP 2023557358A JP 2023557358 A JP2023557358 A JP 2023557358A JP 2024511052 A5 JP2024511052 A5 JP 2024511052A5
- Authority
- JP
- Japan
- Prior art keywords
- treg cells
- cxcr4
- culture medium
- human
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166012P | 2021-03-25 | 2021-03-25 | |
| US63/166,012 | 2021-03-25 | ||
| PCT/US2022/021960 WO2022204523A1 (en) | 2021-03-25 | 2022-03-25 | Populations of enriched regulatory t cells and methods for producing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511052A JP2024511052A (ja) | 2024-03-12 |
| JP2024511052A5 true JP2024511052A5 (https=) | 2025-04-08 |
Family
ID=81308239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557358A Pending JP2024511052A (ja) | 2021-03-25 | 2022-03-25 | 濃縮された制御性ｔ細胞の集団及びその産生方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230066340A1 (https=) |
| EP (1) | EP4314252A1 (https=) |
| JP (1) | JP2024511052A (https=) |
| CN (1) | CN117500914A (https=) |
| AU (1) | AU2022245339A1 (https=) |
| CA (1) | CA3211351A1 (https=) |
| WO (1) | WO2022204523A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4034639A1 (en) | 2019-09-26 | 2022-08-03 | Cellenkos, Inc. | Compositions comprising regulatory t cells and methods of making and using the same |
| CN116410924A (zh) * | 2023-06-08 | 2023-07-11 | 广州正源生物技术有限公司 | 一种体外生产血小板的方法 |
| WO2025042915A1 (en) * | 2023-08-21 | 2025-02-27 | Slate Bio, Inc. | Cell therapy methods using regulatory cells stimulated with interleukin-33 and interleukin-2 |
| WO2025094066A1 (en) * | 2023-10-31 | 2025-05-08 | Cellenkos, Inc. | Uses of regulatory t cells for treating myelofibrosis |
| WO2025171334A1 (en) * | 2024-02-09 | 2025-08-14 | Cedars-Sinai Medical Center | Cell wash, isolation and cryopreservation of frozen umbilical cord blood |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| HK1221260A1 (zh) * | 2013-06-24 | 2017-05-26 | Celgene Corporation | 扩增t细胞的方法 |
| US20190119635A1 (en) * | 2015-05-05 | 2019-04-25 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| JP7118886B2 (ja) * | 2015-06-03 | 2022-08-16 | エアラン セル テクノロジーズ， インコーポレイテッド | 幹細胞からの有益因子の産生および送達のための方法およびデバイス |
| EP3749334B1 (en) * | 2018-02-08 | 2024-12-11 | The Board of Trustees of the Leland Stanford Junior University | Allogenic hematopoietic stem cell transplantation |
| EP4034639A1 (en) * | 2019-09-26 | 2022-08-03 | Cellenkos, Inc. | Compositions comprising regulatory t cells and methods of making and using the same |
-
2022
- 2022-03-25 AU AU2022245339A patent/AU2022245339A1/en active Pending
- 2022-03-25 EP EP22716729.3A patent/EP4314252A1/en active Pending
- 2022-03-25 US US17/704,623 patent/US20230066340A1/en active Pending
- 2022-03-25 CA CA3211351A patent/CA3211351A1/en active Pending
- 2022-03-25 WO PCT/US2022/021960 patent/WO2022204523A1/en not_active Ceased
- 2022-03-25 JP JP2023557358A patent/JP2024511052A/ja active Pending
- 2022-03-25 CN CN202280018247.9A patent/CN117500914A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024511052A5 (https=) | ||
| US20230000919A1 (en) | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions | |
| Noort et al. | Mesenchymal stem cells promote engraftment of human umbilical cord blood–derived CD34+ cells in NOD/SCID mice | |
| Berg et al. | Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells | |
| JP2006506987A (ja) | 自己免疫および臓器または造血幹細胞移植に関連する免疫学的欠損を有する患者における免疫レパートリー回復のための組成物および方法 | |
| JP2006525013A (ja) | 血液幹細胞の数の増幅のための装置および方法 | |
| JP2023505102A (ja) | ナチュラルキラー細胞を製造する方法およびその組成物 | |
| JP2023523429A5 (https=) | ||
| WO2001038494A1 (en) | Method of proliferating natural killer cells | |
| EP1453949A2 (en) | Production of cell suspensions | |
| US20210087530A1 (en) | Compositions and methods for culturing and expanding cells | |
| Mukhopadhyay et al. | Hematopoietic stem cells: clinical requirements and developments in ex-vivo culture | |
| CN102643783A (zh) | 一种用于免疫细胞治疗的活化单个核细胞的制备方法 | |
| KR20060040671A (ko) | 단구성 기원의 자기 유래 자가 관용성 유도 세포 및약제학적 제제에 있어서의 이의 용도 | |
| CN111808800B (zh) | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 | |
| JPH10510702A (ja) | ヒトおよび非ヒト霊長類の多能性幹、前駆および成熟骨髄細胞の維持、増殖および分化のための系 | |
| US6511848B2 (en) | Process for producing and multiplying lymphocytes | |
| US20250255906A1 (en) | Formulations and methods for cellular therapies involving chimeric antigen receptors | |
| WO2025094833A1 (ja) | ナチュラルキラー細胞の製造方法 | |
| JPH11508140A (ja) | リンパ球を生産し、そして増加させる方法 | |
| CN119119276A (zh) | 一种自然杀伤细胞的制备方法及其在治疗疾病中的用途 | |
| TW200533754A (en) | Preparation method of cytokine-induced killer cells and the application thereof | |
| WO1995002685A1 (en) | Serum-free culture of progenitor cells | |
| EA044224B1 (ru) | ЭКСПАНСИЯ γδ-T-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA049808B1 (ru) | ЭКСПАНСИЯ γΔ-Т-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |